MRSN Stock Overview
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Mersana Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.89 |
| 52 Week High | US$8.34 |
| 52 Week Low | US$2.68 |
| Beta | 1.72 |
| 1 Month Change | 27.36% |
| 3 Month Change | -8.62% |
| 1 Year Change | 61.36% |
| 3 Year Change | 4.55% |
| 5 Year Change | -49.19% |
| Change since IPO | -50.79% |
Recent News & Updates
Recent updates
Mersana gains as FDA grants fast track status for breast cancer drug
Sep 12Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed
Aug 15Taking The Measure Of Mersana Therapeutics
Jan 10Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
Jun 29It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year
Jun 05
Mersana Therapeutics EPS misses by $0.11, misses on revenue
May 10Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Mar 23Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?
Jan 29
Bain Capital discloses 4.8% stake in Mersana Therapeutics
Jan 13Mersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst
Jan 11Mersana slumps as XMT-1536 shows lower response rate in ovarian cancer study
Jan 05Is Mersana Therapeutics, Inc. (NASDAQ:MRSN) Trading At A 42% Discount?
Dec 08Mersana Therapeutics EPS misses by $0.02
Nov 09Shareholder Returns
| MRSN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.3% | -0.8% | 2.9% |
| 1Y | 61.4% | 4.5% | -8.5% |
Return vs Industry: MRSN exceeded the US Biotechs industry which returned 5.3% over the past year.
Return vs Market: MRSN exceeded the US Market which returned -9.1% over the past year.
Price Volatility
| MRSN volatility | |
|---|---|
| MRSN Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: MRSN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: MRSN's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 169 | Anna Protopapas | https://www.mersana.com |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate.
Mersana Therapeutics, Inc. Fundamentals Summary
| MRSN fundamental statistics | |
|---|---|
| Market Cap | US$687.44m |
| Earnings (TTM) | -US$208.27m |
| Revenue (TTM) | US$11.90m |
57.7x
P/S Ratio-3.3x
P/E RatioIs MRSN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRSN income statement (TTM) | |
|---|---|
| Revenue | US$11.90m |
| Cost of Revenue | US$165.04m |
| Gross Profit | -US$153.14m |
| Other Expenses | US$55.13m |
| Earnings | -US$208.27m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.09 |
| Gross Margin | -1,286.46% |
| Net Profit Margin | -1,749.59% |
| Debt/Equity Ratio | 27.5% |
How did MRSN perform over the long term?
See historical performance and comparison